Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rubicon ResearchNSE:RUBICON +1.45%18 Days Payable is 203.43 as of Mar. 2026, which is 1% above its 10-year median of 202.27. GuruFocus rates NSE:RUBICON with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 926 Drug Manufacturers companies, Rubicon Research ranks better than 87.69% on this metric.
The historical rank and industry rank for Rubicon Research's Days Payable or its related term are showing as below:
NSE:RUBICON'
s Days Payable Range Over the Past 10 Years
Min: 169.69 Med: 202.27 Max: 285.06
Current: 230.91
During the past 4 years, Rubicon Research's highest Days Payable was 285.06. The lowest was 169.69. And the median was 202.27.
NSE:RUBICON's Days Payable is ranked better than 87.69% of 926
companies
in the Drug Manufacturers industry
Industry Median: 90.455
vs NSE:RUBICON: 230.91
Rubicon Research's Days Payable
increased
from Dec. 2024 (0.00) to Mar. 2026 (203.43).
It may suggest that Rubicon Researchdelayed paying its suppliers.
Rubicon Research Days Payable Related Terms
Rubicon Research Days Payable Historical Data
* Premium members only.
The historical data trend for Rubicon Research's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:RUBICON vs LLY, JNJ, ABBV: Days Payable Comparison
For the Drug Manufacturers - General subindustry, Rubicon Research's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rubicon Research Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rubicon Research's Days Payable distribution charts can be found below:
* The bar in red indicates where Rubicon Research's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Rubicon Research's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rubicon Research (NSE:RUBICON) has a Days Payable of 203.43 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Rubicon Research and its competitors. This is near median its historical median of 202.27. Over the past decade, Rubicon Research's Days Payable has ranged from 169.69 to 285.06. According to the industry distribution chart, Rubicon Research ranks #114 out of 926 companies in the Drug Manufacturers industry, placing it in the top 12.3%.
Is Rubicon Research's Days Payable too high?
Rubicon Research's current Days Payable of 203.43 is near median its 10-year median of 202.27. Over the past 10 years, this metric has ranged from a low of 169.69 to a high of 285.06. The Drug Manufacturers industry median Days Payable is 90.46. Rubicon Research's value of 203.43 is 124.9% above this industry median. Based on the distribution chart, Rubicon Research ranks #114 out of 926 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Rubicon Research has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Rubicon Research's Days Payable compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Rubicon Research ranks #114 out of 926 companies for Days Payable. This places Rubicon Research in the top 12% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.46. Rubicon Research's value of 203.43 is 124.9% above this benchmark. Historically, Rubicon Research's own Days Payable has ranged from 169.69 to 285.06 over the past decade. While the company's 10-year median is 202.27 vs. the industry median of 90.46, Rubicon Research has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.46, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rubicon Research's current Days Payable of 203.43 is 124.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Rubicon Research and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rubicon Research's current Days Payable is 203.43, which is near median its own 10-year median of 202.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rubicon Research stock overvalued right now?
Rubicon Research (NSE:RUBICON) has a current Days Payable of 203.43. The current Days Payable is 203.43, which is near median its 10-year median of 202.27 and 124.9% above the Drug Manufacturers industry median of 90.46. Rubicon Research's overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Rubicon Research (NSE:RUBICON), the current Days Payable is 203.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rubicon Research Ltd is a pharmaceutical formulations company specializing in developing, manufacturing, and marketing branded specialty and generic prescription products. Starting as a provider of contract formulation development services, the company expanded to operate an oral solids manufacturing facility in India, offering contract development and manufacturing services for regulated markets. The company's diverse product portfolio covers multiple therapeutic areas, including analgesics and pain management, CVS, CNS, hypokalemia, skeletal muscle relaxants, NRT, gastrointestinal, metabolic, and immunosuppressants. The company operates in India, the USA, and other markets, with the majority of its revenue coming from the USA.
18GF Score
Get the complete analysis for NSE:RUBICON
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:RUBICON has been successfully added to your 
